SUSQUEHANNA INTERNATIONAL GROUP, LLP - ALLOGENE THERAPEUTICS INC ownership

ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 178 filers reported holding ALLOGENE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.70 and the average weighting 0.1%.

Quarter-by-quarter ownership
SUSQUEHANNA INTERNATIONAL GROUP, LLP ownership history of ALLOGENE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,034,580
-38.4%
326,366
-3.4%
0.00%
Q2 2023$1,679,741
-39.7%
337,976
-40.0%
0.00%
-100.0%
Q1 2023$2,783,858
+331.0%
563,534
+448.8%
0.00%
Q4 2022$645,857
-74.9%
102,680
-56.8%
0.00%
-100.0%
Q3 2022$2,570,000
+7.3%
237,919
+13.3%
0.00%
Q2 2022$2,395,000
-6.9%
210,012
-25.6%
0.00%
Q1 2022$2,573,000
-72.7%
282,320
-55.3%
0.00%
Q4 2021$9,416,000
+31.6%
631,058
+126.7%
0.00%
Q3 2021$7,155,000
+48.7%
278,423
+50.9%
0.00%
Q2 2021$4,812,000
-40.7%
184,526
-19.8%
0.00%
-100.0%
Q1 2021$8,117,000
+6.0%
229,950
-24.2%
0.00%
Q4 2020$7,660,000
+8.7%
303,480
+62.3%
0.00%
-100.0%
Q3 2020$7,050,000
-22.4%
186,952
-11.9%
0.00%0.0%
Q2 2020$9,087,000
+247.5%
212,213
+57.8%
0.00%
Q1 2020$2,615,000
+11.1%
134,523
+48.5%
0.00%
Q4 2019$2,354,000
-72.0%
90,600
-70.7%
0.00%
-100.0%
Q3 2019$8,421,000
-26.6%
308,947
-27.7%
0.00%
+50.0%
Q2 2019$11,469,000
+212.6%
427,162
+236.6%
0.00%0.0%
Q1 2019$3,669,000
+773.6%
126,900
+713.5%
0.00%
Q4 2018$420,00015,6000.00%
Other shareholders
ALLOGENE THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
VV Manager LLC 1,798,163$76,997,00067.53%
Wildcat Capital Management, LLC 1,515,524$64,895,00022.42%
TPG Group Holdings (SBS) Advisors, Inc. 19,716,306$844,252,00014.91%
REGENTS OF THE UNIVERSITY OF CALIFORNIA 1,279,281$54,779,0007.69%
Coastal Bridge Advisors, LLC 463,117$19,831,0006.33%
DSAM Partners (London) Ltd 235,098$10,067,0002.63%
Casdin Capital, LLC 625,000$26,763,0001.58%
Alpine Global Management, LLC 150,000$6,423,0001.13%
Perceptive Advisors 1,543,790$66,105,0001.07%
Avoro Capital Advisors LLC 1,128,594$48,326,0000.96%
View complete list of ALLOGENE THERAPEUTICS INC shareholders